141 related articles for article (PubMed ID: 14760072)
1. CD26 expression correlates with a reduced sensitivity to 2'-deoxycoformycin-induced growth inhibition and apoptosis in T-cell leukemia/lymphomas.
Aldinucci D; Poletto D; Lorenzon D; Nanni P; Degan M; Olivo K; Rapanà B; Pinto A; Gattei V
Clin Cancer Res; 2004 Jan; 10(2):508-20. PubMed ID: 14760072
[TBL] [Abstract][Full Text] [Related]
2. The expression of CD26 and CD40 ligand is mutually exclusive in human T-cell non-Hodgkin's lymphomas/leukemias.
Carbone A; Gloghini A; Zagonel V; Aldinucci D; Gattei V; Degan M; Improta S; Sorio R; Monfardini S; Pinto A
Blood; 1995 Dec; 86(12):4617-26. PubMed ID: 8541553
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo effects of 2'-deoxycoformycin (Pentostatin) on tumour cells from human gammadelta+ T-cell malignancies.
Aldinucci D; Poletto D; Zagonel V; Rupolo M; Degan M; Nanni P; Gattei V; Pinto A
Br J Haematol; 2000 Jul; 110(1):188-96. PubMed ID: 10930997
[TBL] [Abstract][Full Text] [Related]
4. Effect of deoxycoformycin and Val-boroPro on the associated catalytic activities of lymphocyte CD26 and ecto-adenosine deaminase.
Jeanfavre DD; Woska JR; Pargellis CA; Kennedy CA; Prendergast J; Stearns C; Reilly PL; Barton RW; Bormann BJ
Biochem Pharmacol; 1996 Dec; 52(11):1757-65. PubMed ID: 8986139
[TBL] [Abstract][Full Text] [Related]
5. Human monocytoid leukemia cells are highly sensitive to apoptosis induced by 2'-deoxycoformycin and 2'-deoxyadenosine: association with dATP-dependent activation of caspase-3.
Niitsu N; Yamaguchi Y; Umeda M; Honma Y
Blood; 1998 Nov; 92(9):3368-75. PubMed ID: 9787175
[TBL] [Abstract][Full Text] [Related]
6. Potentiation of growth-inhibitory activity of 9-beta-D-arabinofuranosyladenine by 2'-deoxycoformycin in human cultured cell lines derived from leukemias and lymphomas.
Kuroki Y; Shimoyama M; Inaba S; Hirose M
Jpn J Cancer Res; 1989 May; 80(5):482-9. PubMed ID: 2502523
[TBL] [Abstract][Full Text] [Related]
7. Effects of deoxycoformycin in mice. II. Differences between the drug sensitivities and purine metabolizing enzymes of transplantable lymphomas of varying immunologic phenotypes.
Ratech H; Kim J; Asofsky R; Thorbecke GJ; Hirschhorn R
J Immunol; 1984 Jun; 132(6):3077-84. PubMed ID: 6202772
[TBL] [Abstract][Full Text] [Related]
8. CD26, together with cell surface adenosine deaminase, is selectively expressed on ALK-positive, but not on ALK-negative, anaplastic large cell lymphoma and Hodgkin's lymphoma.
Kameoka J; Ichinohasama R; Inoue H; Yamamoto J; Yokoyama H; Tomiya Y; Yamada M; Ishizawa K; Harigae H; Sawai T; Sasaki T
Leuk Lymphoma; 2006 Oct; 47(10):2181-8. PubMed ID: 17071493
[TBL] [Abstract][Full Text] [Related]
9. Regulation of adenosine receptor engagement by ecto-adenosine deaminase.
Hashikawa T; Hooker SW; Maj JG; Knott-Craig CJ; Takedachi M; Murakami S; Thompson LF
FASEB J; 2004 Jan; 18(1):131-3. PubMed ID: 14630704
[TBL] [Abstract][Full Text] [Related]
10. CD26 in T-cell lymphomas: a potential clinical role?
Verstovsek S; Cabanillas F; Dang NH
Oncology (Williston Park); 2000 Jun; 14(6 Suppl 2):17-23. PubMed ID: 10887640
[TBL] [Abstract][Full Text] [Related]
11. CD26/dipeptidyl peptidase IV expression in human lymphomas is restricted to CD30-positive anaplastic large cell and a subset of T-cell non-Hodgkin's lymphomas.
Carbone A; Cozzi M; Gloghini A; Pinto A
Hum Pathol; 1994 Dec; 25(12):1360-5. PubMed ID: 8001932
[TBL] [Abstract][Full Text] [Related]
12. Regulation of epithelial and lymphocyte cell adhesion by adenosine deaminase-CD26 interaction.
Ginés S; Mariño M; Mallol J; Canela EI; Morimoto C; Callebaut C; Hovanessian A; Casadó V; Lluis C; Franco R
Biochem J; 2002 Jan; 361(Pt 2):203-9. PubMed ID: 11772392
[TBL] [Abstract][Full Text] [Related]
13. Pentostatin in T-non-Hodgkin's lymphomas: efficacy and effect on CD26+ T lymphocytes.
Dang NH; Hagemeister FB; Duvic M; Romaguera JE; Younes A; Jones D; Samuels B; Fayad LE; Pro B; Samaniego F; Sarris A; Goy A; McLaughlin P; Tong AT; Walker PL; Tiongson LP; Smith TL; Huh YO; Morimoto C; Rodriguez MA
Oncol Rep; 2003; 10(5):1513-8. PubMed ID: 12883733
[TBL] [Abstract][Full Text] [Related]
14. Gain of CD26 expression on the malignant T-cells in relapsed erythrodermic leukemic mycosis fungoides.
Cedeno-Laurent F; Wysocka M; Obstfeld AE; Novoa RA; Vittorio CC; Kim EJ; Weng WK; Rook AH
J Cutan Pathol; 2017 May; 44(5):462-466. PubMed ID: 28083948
[TBL] [Abstract][Full Text] [Related]
15. CD26/dipeptidyl peptidase IV does not work as an adenosine deaminase-binding protein in rat cells.
Iwaki-Egawa S; Watanabe Y; Fujimoto Y
Cell Immunol; 1997 Jun; 178(2):180-6. PubMed ID: 9225009
[TBL] [Abstract][Full Text] [Related]
16. Characterization of adenosine deaminase binding to human CD26 on T cells and its biologic role in immune response.
Dong RP; Kameoka J; Hegen M; Tanaka T; Xu Y; Schlossman SF; Morimoto C
J Immunol; 1996 Feb; 156(4):1349-55. PubMed ID: 8568233
[TBL] [Abstract][Full Text] [Related]
17. Induction of differentiation of human myeloid leukemia cells by 2'-deoxycoformycin in combination with 2'-deoxyadenosine.
Niitsu N; Umeda M; Honma Y
Biochem Biophys Res Commun; 1997 Sep; 238(1):100-6. PubMed ID: 9299460
[TBL] [Abstract][Full Text] [Related]
18. Rat brain adenosine deaminase after 2'-deoxycoformycin administration: biochemical properties and evidence for reduced enzyme levels detected by 2'-[3H]deoxycoformycin ligand binding.
Padua RA; Geiger JD; Delaney SM; Nagy JI
J Neurochem; 1992 Feb; 58(2):421-9. PubMed ID: 1729390
[TBL] [Abstract][Full Text] [Related]
19. Characterization of three T-lymphoid cell lines with distinct sensitivities to deoxyadenosine plus deoxycoformycin.
Duan DS; Smith W; Sadée W; Cowan MJ
Thymus; 1992 Feb; 19(1):1-11. PubMed ID: 1373528
[TBL] [Abstract][Full Text] [Related]
20. CD26: a novel treatment target for T-cell lymphoid malignancies? (Review).
Sato K; Dang NH
Int J Oncol; 2003 Mar; 22(3):481-97. PubMed ID: 12579300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
